ReviewAnalytical and bioanalytical chemistry2026
Advancing precision medicine with bioelectroanalytical technologies leveraging unconventional nucleic acid forms.
Review in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The non-canonicity at the DNA and RNA levels that characterizes the intriguing world of nucleic acids is redefining our understanding of gene regulation, cellular responses, and the mechanisms that orchestrate the emergence, onset, and evolution of diseases. These atypical, mysterious, and Watson-Crick deviating DNA and RNA structural configurations include circular RNAs (circRNAs), transfer RNA-derived fragments (tRFs), G-quadruplexes (G4s), and related biotargets, such as telomerase, and are increasingly recognized as pivotal biomarkers and functional targets in precision and personalized medicine, particularly for the moment, in the neurodegenerative and oncological landscapes. Their structural uniqueness and disease-specific expression patterns and profiles position them as ideal candidates for the early diagnosis and tailored therapies. In turn, electrochemical biosensing, despite guaranteeing high sensitivity, low cost, and suitability for point-of-care applications, represents a powerful yet underutilized tool for detecting these complex promising molecular entities. Strikingly, and to the best of our knowledge, there is currently no dedicated vision addressing this important issue. Therefore, with the aim of contributing to bridge this void, this review compiles the latest efforts recently made for unlocking the diagnostic and therapeutic potentials of these enigmatic and naturally occurring biostructures and their most relevant related biotargets through the employment of bioelectroanalytical technologies.
Indexed as
Identifiers
41175216What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.